The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new analyses from studies of sotatercept, Merck’s novel investigational activin ...

Moderna (MRNA) stock is in focus as the mRNA-based cancer drug with Merck's (MRK) Keytruda cut melanoma recurrence/death risk ...

Merck is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world. The drugmaker will cut administrative, ...

While increasing collaboration between payers and providers was a major theme at HIMSS in Orlando last week, one other major stakeholder has been quite a bit harder to find in conversations about big ...

In the latest trading session, Merck (MRK) closed at $111.11, marking a +1.52% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 1.16%. Elsewhere, the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, today announced that it has entered a strategic collaboration with Merck KGaA, Darmstadt, ...

Michael Rosenblatt, dean of Tufts University School of Medicine (TUSM), yesterday morning announced his decision to step down effective Dec. 20. He will take up the newly created position of chief ...